Efficacy and safety of Abelmoschus manihot capsule combined with ACEI/ARB on diabetic kidney disease: a systematic review and meta analysis

Ying Tan, Ziqi Zhang, Peipei Zhou, Qiling Zhang, Nan Li, Qianhua Yan, Liji Huang, Jiangyi YuFrontiers in Pharmacology 2024 · DOI

Abstract

Diabetic kidney disease (DKD) is a critical microvascular complication of diabetes and a primary driver of chronic kidney disease (CKD) globally. While renin-angiotensin-aldosterone system inhibitors (RASIs) are the standard of care, adjunctive therapies are often sought to improve outcomes. This systematic review and meta-analysis evaluates the efficacy and safety of combining Abelmoschus manihot (AM) capsules with RASI therapy. Analyzing 32 randomized controlled trials (RCTs) involving 2,881 patients, the study found that the combination therapy significantly improved renal biomarkers and reduced proteinuria compared to RASI monotherapy, maintaining a favorable safety profile.

Introduction

Diabetic kidney disease (DKD) remains the leading cause of end-stage kidney disease. Current clinical guidelines emphasize the use of ACE inhibitors (ACEIs) or Angiotensin-Receptor Blockers (ARBs) to manage blood pressure and reduce protein leakage. Despite these interventions, many patients experience persistent renal decline. In China, Abelmoschus manihot (AM) capsules, a proprietary Chinese patent medicine, are widely utilized as a complementary treatment. This paper provides a high-quality synthesis of clinical evidence to determine if the combination of AM and RASI offers superior therapeutic benefits over standard care.

Methods

The researchers conducted a systematic search across major English and Chinese databases, including PubMed, Cochrane Library, Embase, CNKI, and SinoMed, for RCTs published through March 2023. The inclusion criteria focused on studies comparing AM capsules plus RASI against RASI alone in DKD patients. Two independent investigators performed data extraction and assessed study quality using the Cochrane risk of bias tool. Meta-analysis was conducted using RevMan 5.4, employing random-effects models to account for expected study heterogeneity.

Results

The meta-analysis included 32 RCTs with a total of 2,881 patients (1,442 in the treatment group; 1,439 in the control group). The results demonstrated significant clinical improvements in the combination therapy group across several key metrics:

  • Proteinuria Reduction: The AM + RASI group showed a significantly greater reduction in 24-hour urine total protein (24h-UTP) by an average of 442.05 mg (p < 0.00001) and urinary albumin excretion rate (UAER) by 30.53 μg/min (p < 0.00001).
  • Renal Function Preservation: Serum creatinine (Scr) levels decreased by 6.80 μmol/L (p < 0.0001), and blood urea nitrogen (BUN) decreased by 0.59 mmol/L (p = 0.01), indicating improved filtration.
  • Subgroup Insights: The combination of AM and ARB appeared more effective in reducing UAER than the AM and ACEI combination. Furthermore, patients with higher baseline protein leakage (>2g/24h) or elevated creatinine levels saw more pronounced benefits from the addition of AM.
Summary of meta-analysis results showing improvements in renal markers and a good safety profile for AM + RASI therapy.

Safety Profile

A critical finding of this review is the safety of the integrated approach. The analysis of adverse reactions (such as gastrointestinal discomfort or dizziness) showed no statistically significant difference between the combination group and the control group (OR = 1.06; 95% CI: 0.66, 1.69; p = 0.82). This suggests that AM capsules do not introduce additional toxicity when used alongside standard Western pharmacological treatments.

Discussion and Limitations

The study suggests that AM may work synergistically with RASIs by reducing inflammation and inhibiting renal fibrosis. However, the authors note several limitations that require cautious interpretation:

  1. High Heterogeneity: Significant variability ($I^2 > 90\%$) was observed, likely due to differences in drug dosages, patient demographics, and disease stages.
  2. Geographic Bias: Most trials were conducted in China and published in Chinese, which may affect the generalizability of the findings to other populations.
  3. Study Duration: Most trials were relatively short (8–24 weeks), leaving the long-term efficacy and safety of AM in chronic DKD management unclear.
  4. Methodological Quality: Some studies lacked detailed reporting on randomization and blinding, introducing potential bias.

Conclusion

Combining Abelmoschus manihot capsules with RASI therapy appears to be a superior strategy for managing DKD compared to RASI monotherapy, particularly in reducing proteinuria and stabilizing renal function. While the safety profile is encouraging, the high heterogeneity of current data underscores the need for large-scale, multi-center, double-blind RCTs with longer follow-up periods to solidify these findings in international clinical practice.

Summary updated

Abstract

<b>Background:</b> Diabetic kidney disease (DKD) is one of the most serious microvascular complications of diabetes, with the incidence rate increasing yearly, which is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease. Abelmoschus Manihot capsule, as a proprietary Chinese patent medicine, is widely used for treating CKD in China. Currently, the combination of Abelmoschus Manihot (AM) capsule and renin-angiotensin-aldosterone system inhibitor (RASI) has gained popularity as a treatment option for DKD, with more and more randomized control trials (RCTs) in progress. However, the high-quality clinical evidence supporting its application in DKD is still insufficient. <b>Aim of the study:</b> To comprehensively and systematically evaluate the efficacy and safety of AM capsule combined with RASI in the treatment of DKD. <b>Materials and methods:</b> English and Chinese databases such as Pubmed, Cochrane Library, Embase, CNKI, SinoMed, WF, and VIP were searched to collect the RCTs of AM capsule in treatment of DKD. Then Two investigators independently reviewed and extracted data from the RCTs which met the inclusion criteria. The quality of the data was assessed using the Cochrane risk of bias assessment tool, and meta-analysis was performed using RevMan 5.4 software. <b>Results:</b> 32 RCTs with a total of 2,881 DKD patients (1,442 in the treatment group and 1,439 in the control group) were included. The study results showed that AM capsule combined with RASI could be more effective in decreasing 24h-UTP [MD = -442.05, 95% CI (-609.72, -274.38), <i>p</i> < 0.00001], UAER [MD = -30.53, 95% CI (-39.10, -21.96), <i>p</i> < 0.00001], UACR [MD = -157.93, 95% CI (-288.60, -27.25), <i>p</i> < 0.00001], Scr [MD = -6.80, 95% CI (-9.85, -3.74), <i>p</i> < 0.0001], and BUN [MD = -0.59, 95% CI (-1.07, -0.12), <i>p</i> = 0.01], compared to using RASI alone. According to the subgroup analyses, the combination of AM and ARB seems to be more effective in reducing UAER than the combination of ACEI, and the addition of AM may achieve a more significant clinical effect on decreasing Scr for DKD patients with 24h-UTP>2 g or Scr>110-133 μmol/L and >133 μmol/L. Furthermore, no additional adverse reactions were observed in the combination group [OR = 1.06; 95%CI: (0.66, 1.69), <i>p</i> = 0.82]. <b>Conclusion:</b> Combining AM with RASI may be a superior strategy for DKD treatment compared to RASI monotherapy. However, due to significant heterogeneity, the results should be interpreted with great caution, and more high-quality RCTs with multi-centers, different stages of DKD, large sample sizes, and long follow-up periods are still needed to improve the evidence quality of AM for DKD in the future. <b>Systematic Review Registration:</b> https://www.crd.york.ac.uk/PROSPERO/#recordDetails; Identifier CRD42022351422.
BibTeX
@inproceedings{tan2024efficacy,
  author = {Ying Tan and Ziqi Zhang and Peipei Zhou and Qiling Zhang and Nan Li and Qianhua Yan and Liji Huang and Jiangyi Yu},
  title = {{Efficacy and safety of Abelmoschus manihot capsule combined with ACEI/ARB on diabetic kidney disease: a systematic review and meta analysis}},
  booktitle = {Frontiers in Pharmacology},
  year = {2024},
  doi = {10.3389/fphar.2023.1288159},
}
Figure